Assyro AI

Orange Book product · Brand (NDA)

TYMLOS

ABALOPARATIDE

Brand (NDA)NDA 208743RX RADIUS

At a glance

Apr 28, 2017

Approved

Brand (NDA)

Application

Not listed

TE code

12

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Apr 28, 2017

    9 yr 3 mo ago

  2. Today

  3. Patent 8748382 expires

    Listed method-of-use patent (U-3543) expiration.

    Oct 03, 2027

    in 1 yr 4 mo

  4. Patent 8748382 expires

    Listed method-of-use patent (U-2009) expiration.

    Oct 03, 2027

    in 1 yr 4 mo

  5. Patent 8148333 expires

    Listed drug product patent expiration.

    Nov 08, 2027

    in 1 yr 5 mo

  6. Patent 7803770 expires

    Listed method-of-use patent (U-2009) expiration.

    Apr 28, 2031

    in 4 yr 11 mo

  7. Patent RE49444 expires

    Listed method-of-use patent (U-2009) expiration.

    Apr 28, 2031

    in 4 yr 11 mo

  8. Patent RE49444 expires

    Listed method-of-use patent (U-3543) expiration.

    Apr 28, 2031

    in 4 yr 11 mo

  9. Patent 10996208 expires

    Listed drug product patent expiration.

    Apr 30, 2038

    in 12 yr

  10. Patent 11782041 expires

    Listed drug product patent expiration.

    Apr 30, 2038

    in 12 yr

  11. Patent 11782041 expires

    Listed drug product patent expiration.

    Apr 30, 2038

    in 12 yr

  12. Patent 11977067 expires

    Listed drug product patent expiration.

    Apr 30, 2038

    in 12 yr

  13. Patent 11255842 expires

    Listed method-of-use patent (U-3322) expiration.

    Jan 10, 2040

    in 13 yr 9 mo

  14. Patent 11680942 expires

    Listed method-of-use patent (U-3322) expiration.

    Jan 10, 2040

    in 13 yr 9 mo

Pharmaceutical detail

Active ingredient

ABALOPARATIDE

Strength

3.12MG/1.56ML (2MG/ML)

Dosage form

SOLUTION

Route

SUBCUTANEOUS

TE code

Not listed

Application

NDA 208743

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (12)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
8748382Oct 03, 2027in 1 yr 4 mo
U-3543
8748382Oct 03, 2027in 1 yr 4 mo
U-2009
8148333Nov 08, 2027in 1 yr 5 mo
Product
7803770Apr 28, 2031in 4 yr 11 mo
U-2009
RE49444Apr 28, 2031in 4 yr 11 mo
U-2009
RE49444Apr 28, 2031in 4 yr 11 mo
U-3543
10996208Apr 30, 2038in 12 yr
Product
11782041Apr 30, 2038in 12 yr
ProductU-2009
11782041Apr 30, 2038in 12 yr
ProductU-3543
11977067Apr 30, 2038in 12 yr
Product
11255842Jan 10, 2040in 13 yr 9 mo
U-3322
11680942Jan 10, 2040in 13 yr 9 mo
U-3322
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.